Nimotuzumab


Generic Medicine Info
Indications and Dosage
Intravenous
Malignant glioma
Adult: 200 mg wkly as continuous IV infusion w/in 60 min in combination w/ radiation treatment of 2 Gy once daily, 5 days/wk to a total dose of 50-60 Gy for 6 wk.
Child: As monotherapy in 2 consecutive phases. Induction phase: 150 mg/m2 BSA wkly for 6 wk. After induction phase, patients w/o progressive disease upon 8th-wk evaluation will be treated in the consolidation phase, where it is given 150 mg/m2 BSA every 3 wk until disease progression. Administer via continuous IV infusion w/in 30 min.
Reconstitution
Dilute in 250 mL of NaCl 0.9% soln.
Contraindications
Pregnancy and lactation.
Special Precautions
Patients previously treated w/ the murine monoclonal antibody ior EGF/r3. Patients w/ chronic diseases in decompensate phase (e.g. cardiac dysfunction, DM, arterial HTN or history of severe allergic reaction).
Adverse Reactions
Chills, pyrexia, fatigue, asthenia, headache, dizziness, nausea, vomiting, loose stools, tremors, pruritus, rash, HTN and fluctuation in BP. Rarely, myalgia, somnolence, disorientation, haematuria and elevated liver enzymes.
Action
Description: Nimotuzumab is a humanised monoclonal antibody which requires bivalent binding for stable attachment to the cell surface. It is therefore bound selectively to cells w/ high levels of the epidermal growth factor receptor (EGFR) expression. Nimotuzumab inhibits epidermal growth factor (EGF) binding and tumour cell growth.
Pharmacokinetics:
Distribution: Mainly distributed in the liver, spleen, heart, kidney and bladder. Distributed into breast milk.
Storage
Store between 2-8°C. Do not freeze or shake.
References
Anon. Nimotuzumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 22/01/2014.

Buckingham R (ed). Nimotuzumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 22/01/2014.

Theracim (Inoogene Kalbiotech). MIMS Philippines. http://www.mims.com/philippines. Accessed 22/01/2014.

Disclaimer: This information is independently developed by MIMS based on Nimotuzumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in